Sequential Trio Whole Exome Sequencing

Clinical Use

Use

The Sequential Trio Whole Exome Sequencing test is designed to identify DNA changes linked to medical concerns, analyzed through next-generation sequencing of exons across thousands of genes. This comprehensive approach contrasts with panel tests, offering insights when earlier proband-only exomes did not yield adequate diagnoses. Doctors can discover de novo mutations or compound heterozygous variations that influence the patient's health condition. The results are interpreted by experts, associating identified genetic variations with potential medical conditions for better clinical decision-making.

Special Instructions

Testing for the Sequential Trio Whole Exome Sequencing requires parental samples alongside the proband. If no further testing is needed, previous exome data will be utilized. It is crucial that both parents submit samples; otherwise, the test cannot be performed. For information regarding previous submissions or to verify sample requirements, please contact client services.

Limitations

Limitations include the dependency on prior proband-only exome tests and the requirement for parental samples, which may restrict patient eligibility. Variations identified may not always correlate directly with clinical findings, and negative results do not eliminate the possibility of genetic influences. Should technical issues arise, the ability to interpret results might be compromised. Furthermore, as sequencing technology improves, future advancements may render results progressively outdated. Misinterpretation of variants can occur, particularly with variants of uncertain significance.

Test Details

New York Approved